. The responses of HepG2 cells cultured in well plates (2D) to (A) Cisplatin, (B) Resvertrol, and (C) TPZ under various oxygen tensions (1%, 10%, and 20%) after 48-hour treatments (n=8). The cell viabilities are characterized by seeding 100 μl of the cell suspension with a density of 50 cells/μl into each well of a 96 well plate. The cells are incubated overnight before the drug treatments. The cells are then treated with three anti-cancer drugs with various concentrations in growth medium under desired oxygen tensions in a cell incubator with oxygen tension control (Heracell 240i, Thermo Scientific Inc., Waltham, MA) for 48 hours. The quantitative cell viabilities are estimated using PrestoBlue Cell Viability Reagent (A-13261, Invitrogen). Following the protocol provided from the manufacturer, 10 μl of PrestoBlue is added to each cell culture well. The plate is then incubated at 37 o C and protected from direct light in a cell incubator for 20 minutes. The fluorescence signal from each cell culture well is detected using a commercial microplate reader (Synergy 2, BioTek Instruments, Inc., Winooski, VT) with excitation and emission wavelengths of 530/25 nm and 590/30 nm, respectively. Figure S2 . Microscopic photos of the HepG2 spheroids harvested from the microfluidic device, and singles after 5-minute dissociation from the spheroids. In average, more than 93% of the cells can be dissociated into single cell populations. Scale bar is 100 μm. 
